找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Drug Discovery and Drug Development; The Indian Narrative Madhu Dikshit Book 2021 Springer Nature Singapore Pte Ltd. 2021 drug formulation.

[復(fù)制鏈接]
樓主: Malinger
21#
發(fā)表于 2025-3-25 05:56:35 | 只看該作者
22#
發(fā)表于 2025-3-25 07:59:07 | 只看該作者
,Regulatory Requirements and Quality Standards in India’s Clinical Trials Journey,e, transparent, and effective regulations for CTs to enable faster accessibility of new drug molecules in the country. The New Drugs and Clinical Trials Rules 2019 is a step in that direction. This chapter attempts to give an overview of the regulatory developments in the context of changed scenario
23#
發(fā)表于 2025-3-25 12:12:28 | 只看該作者
24#
發(fā)表于 2025-3-25 18:21:30 | 只看該作者
rch (NDDR) journey to date. Gathering contributions from prominent researchers in the Indian Pharma Industry and Academia, this book highlights their efforts, achievements, and the status quo of Indian NDDR.??.978-981-15-8004-8978-981-15-8002-4
25#
發(fā)表于 2025-3-25 22:48:45 | 只看該作者
https://doi.org/10.1007/978-3-7908-2367-7vel class antibiotic mersacidin and phase 3 clinical stage/regulatory approval of Orchid’s OCID 5090, and Wockhardt’s levonadifloxacin, alalevonadifloxacin, nafithromycin, and zidebactam are discussed.
26#
發(fā)表于 2025-3-26 01:14:56 | 只看該作者
Network Economics in Software Marketsse in India by 2017; however, until date, target could not be achieved. This underscores the need for development of new antileishmanial agent that is administered orally. Research efforts to identify new chemical entities, using both phenotypic and target-based screening led to the identification o
27#
發(fā)表于 2025-3-26 05:19:01 | 只看該作者
28#
發(fā)表于 2025-3-26 09:52:09 | 只看該作者
29#
發(fā)表于 2025-3-26 15:12:15 | 只看該作者
30#
發(fā)表于 2025-3-26 18:36:13 | 只看該作者
Traditional Medical System (TMS) for Sustainable Healthcare in India,ealth care system. As per WHO recommendation, TM should be a part of health and wellness and promote safe and effective use. It can be done by proper regulation, research and integrate products, practitioners and practice into TM health systems. This can be assigned that the sum total of the knowled
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-5 17:06
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
浦江县| 楚雄市| 观塘区| 宜阳县| 西和县| 光山县| 衡山县| 五寨县| 崇信县| 云梦县| 印江| 井冈山市| 北海市| 乐安县| 墨玉县| 汝州市| 綦江县| 娱乐| 广水市| 麟游县| 永春县| 浪卡子县| 常山县| 开原市| 定远县| 银川市| 新昌县| 舒城县| 水城县| 宜川县| 留坝县| 云梦县| 定襄县| 闻喜县| 洮南市| 霍邱县| 平凉市| 德庆县| 安龙县| 太保市| 丰台区|